Cancers Treated:
Specializing In:
Endoscopic surgery Robotic surgery Urinary Incontinence Vasectomy Erectile dysfunction management Andrology Benign prostatic enlargement treatment Stone Disease Prostate Cancer ScreeningResearch Interests:
Tumor biology and immunology in bladder and kidney cancerAbout Jorge Daza
Biography:
Dr. Daza was appointed to Roswell Park Care Network in 2024. He serves in the Department of Urology. Dr. Daza attended Universidad Militar Nueva Granada In Bogota, Colombia where he earned his medical degree in 2011. He subsequently completed his residency in Urology in 2017 at the same institution. He joined the Icahn School of Medicine at Mount Sinai in New York, NY in 2018 as an Associate Researcher at the Department of Urology where he conducted translational and clinical research in bladder and kidney cancer. In 2021, he joined Roswell Park Comprehensive Cancer Center as a Society of Urologic Oncology Fellow and completed his training in Urologic Oncology.
Dr. Daza specializes in the care of patients with general urological disorders and genitourinary cancers. He provides expertise in robot-assisted, endoscopic, and open-operative approaches.
Dr. Daza has authored and co-authored many peer-reviewed publications and abstracts on urology and genitourinary cancers. He serves as a reviewer for multiple journals, including the Journal of Urologic Oncology, the Journal of Endourology, and the World Journal of Urology.
Dr. Daza is a member of the American Urologic Association (AUA) and the Society of Urologic Oncology.
Positions
- Urologist
- Roswell Park Lockport
Background
Education and Training:
- 2005-2011 - MD - Universidad Militar Nueva Granada, Bogota, Colombia
Residency:
- 2013-2017 - Urology, Universidad Militar Nueva Granada, Bogotá, Colombia
Fellowship:
- 2021-2023 - Society of Urologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Professional Memberships:
- Society of Urologic Oncology
- American Urological Association
Professional Experience:
- 2018-2021 - Associate Researcher, Icahn Medical School of Medicine at Mount Sinai Department of Urology, New York, NY
Honors & Awards:
- 2020 - Best poster in session – Radioproteomic analysis as a potential predictor of renal tumor histopathology, American Urological Association, Washington, DC
- 2019 - Best poster in session, Multi Lineage Plasticity and Heterogeneity in Muscle Invasive Bladder Cancer, American Urological Association Chicago, IL
- 2015 - Best Podium Presentation - Validacion Del Nomograma Del Prostate Cancer Prevention Trial Risk Calculator 2.0 En Pacientes Con Cancer De Prostata De Alto Riesgo, Colombian Urological Society
Publications
Yu H, Sfakianos JP, Wang L, Hu Y, Daza J, Galsky MD, Sandhu HS, Elemento O, Faltas BM, Farkas AM, Bhardwaj N, Zhu J, Mulholland DJ. Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms. Mol Cancer Ther. 2022 Nov 3;21(11):1729-1741. doi: 10.1158/1535-7163.MCT-22-0130. PMID: 36129800; PMCID: PMC9706595.
Salomé B, Sfakianos JP, Ranti D, Daza J, Bieber C, Charap A, Hammer C, Banchereau R, Farkas AM, Ruan DF, Izadmehr S, Geanon D, Kelly G, de Real RM, Lee B, Beaumont KG, Shroff S, Wang YA, Wang YC, Thin TH, Garcia-Barros M, Hegewisch-Solloa E, Mace EM, Wang L, O'Donnell T, Chowell D, Fernandez-Rodriguez R, Skobe M, Taylor N, Kim-Schulze S, Sebra RP, Palmer D, Clancy-Thompson E, Hammond S, Kamphorst AO, Malmberg KJ, Marcenaro E, Romero P, Brody R, Viard M, Yuki Y, Martin M, Carrington M, Mehrazin R, Wiklund P, Mellman I, Mariathasan S, Zhu J, Galsky MD, Bhardwaj N, Horowitz A. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell. 2022 Sep 12;40(9):1027-1043.e9. doi: 10.1016/j.ccell.2022.08.005. PMID: 36099881; PMCID: PMC9479122.
Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM, Mulholland DJ. Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nat Commun. 2020 May 21;11(1):2540. doi: 10.1038/s41467-020-16162-3. PMID: 32439865; PMCID: PMC7242345.
Daza J, Salomé B, Okhawere K, Bane O, Meilika KN, Korn TG, Qi J, Xe H, Patel M, Brody R, Kim-Schulze S, Sfakianos JP, Lewis S, Rich JM, Zuluaga L, Badani KK, Horowitz A. Urine supernatant reveals a signature that predicts survival in clear-cell renal cell carcinoma. BJU Int. 2023 Jul;132(1):75-83. doi: 10.1111/bju.15989. Epub 2023 Mar 7. PMID: 36797809.
Daza J, Salomé B, Okhawere K, Bane O, Meilika KN, Korn TG, Qi J, Xe H, Patel M, Brody R, Kim-Schulze S, Sfakianos JP, Lewis S, Rich JM, Zuluaga L, Badani KK, Horowitz A. Urine supernatant reveals a signature that predicts survival in clear-cell renal cell carcinoma. BJU Int. 2023 Jul;132(1):75-83. doi: 10.1111/bju.15989. Epub 2023 Mar 7. PMID: 36797809.